Search This Blog

Wednesday, March 31, 2021

Aptevo Reports 2020 Results, Business Update

 Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing

Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Agreement

https://www.biospace.com/article/releases/aptevo-therapeutics-reports-2020-financial-results-and-provides-business-update/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.